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ABSTRACT
Mannan-binding lectin–associated serine protease 3 (MASP-3) regulates the alternative pathway of complement and is
predominantly synthesized in the liver. The role of liver-derived MASP-3 in the pathogenesis of rheumatoid arthritis (RA) is unknown.
We hypothesized that liver-derived MASP-3 is essential for the development of joint damage and that targeted inhibition of MASP-3
in the liver can attenuate arthritis. We used MASP-3–specific small interfering RNAs (siRNAs) conjugated to N-acetylgalactosamine
(GalNAc) to specifically target the liver via asialoglycoprotein receptors. Active GalNAc–MASP3–siRNA conjugates were identified,
and in vivo silencing of liver MASP-3 mRNA was demonstrated in healthy mice. The s.c. treatment with GalNAc–MASP-3–siRNAs
specifically decreased the expression of MASP-3 in the liver and the level of MASP-3 protein in circulation of mice without affecting
the levels of the other spliced products. In mice with collagen Ab–induced arthritis, s.c. administration of GalNAc–MASP-3–siRNA
decreased the clinical disease activity score to 50% of controls, with decrease in histopathology scores and MASP-3 deposition. To
confirm the ability to perform MASP-3 gene silencing in human cells, we generated a lentivirus expressing a short hairpin RNA
specific for human MASP-3 mRNA. This procedure not only eliminated the short-term (at day 15) expression of MASP-3 in HepG2 and
T98G cell lines but also diminished the long-term (at day 60) synthesis of MASP-3 protein in T98G cells. Our study demonstrates that
isoform-specific silencing of MASP-3 in vivo modifies disease activity in a mouse model of RA and suggests that liver-directed MASP3
silencing may be a therapeutic approach in human RA. ImmunoHorizons, 2018, 2: 274–295.
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INTRODUCTION
Rheumatoid arthritis (RA), a crippling inﬂammatory autoimmune
disease of the joints, aﬀects ;0.24% of the world population (1).
The severe morbidity of this condition indicates that this dis-
ease will impact the public health care system dramatically (2).
Although the advent of biologics for the treatment of RA has
improved outcomes, ;40% of patients respond partially or not
at all. Despite clinical improvement aﬀorded by these biologic
and small molecule therapeutics, the radiological damage in RA
can continue over time because of the underlying inﬂammatory
processes that are not fully controlled by the existing drugs on
the market (3).
We and others have extensively probed the complement net-
work to identify targets suitable for therapeutic development (4–7).
Because of the complexity of human RA, current drug targets in-
clude cytokines (TNF-a, IL-1, and IL-6) as well as cells (B cells and
T cells). We suggest that complement may serve as an additional
important therapeutic target to add to the RA armamentarium,
whichalsomayconferbeneﬁt becausecomplementactivationexerts
its function upstream in the inﬂammatory cascade.
The etiology of RA is complex and involves a combination of
environmental, hormonal, genetic, andepigenetic elements leading
to an increased likelihood of developing an immune response
to posttranslationally altered peptides. Citrullinated peptides are
considered a prime example, and the presence of anticitrullinated
peptide Abs (ACPAs) is both disease-speciﬁc and signiﬁcantly
correlated with radiological damage in patients with RA (3). How-
ever, the development of autoantibodies to altered self alone is not
suﬃcient to trigger RA. Rather, a second hit has been postulated to
be required for localization of this immune response to the joint
(8). Ultimately, it appears that the deposition of Ab within the
synovial space leads to the initiation of a joint-speciﬁc immune
response, which becomes self-sustaining. Our hypothesis is that
the liver plays a critical role in this second hit process through
the secretion of potent proinﬂammatory complement proteins.
The complement system is composedofmany soluble proteins
and receptors, a substantial proportion of which are produced
by the liver (9). Other tissues, however, can secrete complement
components, including epithelial, endothelial, and immune cells
(10, 11). The complement system is activated through three dif-
ferent pathways: the classical pathway, the lectin pathway (LP),
and the alternative pathway (AP). All of these pathways converge
with the cleavage of C3 and C5 via C3 and C5 convertases,
respectively, generating C3a, C3b, C5a, and C5b. C3a and C5a
function as general activators of inﬂammatory cells via C3a and
C5a receptors, whereas C5b promotes the assembly of the mem-
brane attack complex C5b-9.
It iswell acceptedbasedonstudiesofcomplement component-
deﬁcient strains inmousemodels of arthritis that this systemplays
an essential role in the development of experimental models of
RA (12–16).Moreover, activated complement fragments have been
found in the synovium of RA patients (15, 17, 18). Additionally, two
mouse models of arthritis (i.e., collagen-induced arthritis and
collagen Ab–induced arthritis [CAIA]) have extensively been
used to successfully test many drugs currently being used for the
treatment of RA (19, 20).
The LP of the complement system is activated when pattern
recognition molecules (PRMs) binds to targets. These PRMs
include mannan-binding lectin (MBL), collectin-L/K (collectin-
10/11), H-ﬁcolin (ﬁcolin-3), L-ﬁcolin (ﬁcolin-2), or M-ﬁcolin
(ﬁcolin-1) (21). Associated with the PRMs are a set of proteases
that link PRM binding to activation of the complement system.
To this end, the liver synthesizes three diﬀerent proteases of the
LP that play this role: MBL-associated serine protease (MASP)-1,
MASP-2, and MASP-3 and two MBL-associated proteins, sMAp
(MAp19 or MAP-2) and MAp44 (MAP-1) (22–25). The MASP1
gene generates via alternative splicing the two proteases MASP-1
andMASP-3 as well asMAp44 (26, 27), whereas theMASP2 gene
generates MASP-2 and sMAp (25).
WhenPRMsbind to relevantpatterns,MASP-1 is activatedand
then promotes the activation of MASP-2, which subsequently
cleaves C4 and C2, thereby generating the C3 convertase, C4b2a
(28). In vitro (not in vivo) studies have shown that MASP-1 is
essential for bacterial LPS but not zymosan-induced AP (29),
indicating that MASP-1 can regulate a speciﬁc AP subset and not
the entire AP. MASP-3 is required for the cleavage of profactor D
(proFD) into mature factor D (FD), an essential factor of the AP
and ampliﬁcation loop, which is engaged and boosts the activity
of all pathways of the complement system (22, 28, 30–33). Mice
lacking MASP-1/3 are strongly resistant to CAIA (14), whereas
mice lacking MASP-2 are partially resistant (34). The individual
roles of MASP-1 and MASP-3 could not be resolved in these
studies, as the knockout of theMASP1 gene eliminates both splice
variants. In addition,MASP-1/32/2 exhibit developmental delays
and small size. Both MASP-1/32/2 mice lacking the enzymes as
well as wild type (WT)mice treatedwith amixture of commercial
MASP-1/3 small interfering RNAs (siRNAs) were protected from
the CAIA (22). Because of the interrelationships of the systems,
the individual role of MASP-1 or MASP-2 or MASP-3, however,
remained to be determined.
RNA interference (RNAi) is a naturally occurring silencing
mechanism that has been used to develop a highly eﬃcient and
targeted technology to silence pathogenic genes using synthetic
siRNAs or intracellularly generated siRNAs using short hairpin
(sh)RNAs. In this study, we used two diﬀerent RNAi delivery ap-
proaches to silence theMASP-3 transcript speciﬁcally in cells and
in mouse liver. We used lentiviral constructs encoding shRNAs
targetingMASP-3 for eﬃcient and long-term silencing ofMASP-3
in human cell lines (35).
The asialoglycoprotein receptor (ASGPR) is highly expressed
on hepatocytes and binds triantennary N-acetylgalactosamine
(GalNAc) ligands with nanomolar aﬃnity (36, 37). The ASGPR
is conserved across species, is highly expressed on hepatocytes
(;500 K/cell) (38–40), and has a 15-min recycling time following
internalization (41). These properties of theASGPR facilitate rapid
https://doi.org/10.4049/immunohorizons.1800053
ImmunoHorizons TREATMENT OF ARTHRITIS WITH A MASP-3 RNAi THERAPEUTIC 275
 by guest on M
ay 29, 2019
http://w
w
w
.im
m
unohorizons.org/
D
ow
nloaded from
 
andspeciﬁcuptakeofGalNAc-siRNAsconjugates intohepatocytes
(reviewed in Ref. 42). The GalNAc-siRNA conjugate technology
has been used to target multiple liver-expressed genes and has
demonstrated robust silencing in preclinical animal models and
clinical studies. As an example, 90% knockdown was obtained of
the liver-expressed transthyretin gene in a phase I study of the
GalNAc-siRNA ALN-TTRsc (reviewed in Ref. 42). More recently,
it has been shown that a single dose of Inclisiran (ALN-PCSsc),
a GalNAc-conjugated siRNA targeting proprotein convertase
subtilisin-kexin type 9 (PCSK9) robustly reduced serum PCSK9
levels, resulting in the lowering of a target for the lowering of
low-density lipoprotein cholesterol for up to 6 mo after a single
dose (43). These studies provide direct clinical proof of concept
that GalNAc-conjugated siRNAi are a good choice for hepatocyte-
targeted delivery of GalNAc–MASP-3–siRNA duplexes to silence
liver-derivedMASP-3expressionandthus tospeciﬁcally investigate
the role of MASP-3 in inﬂammatory arthritis.
Ourﬁrst objective in this studywas to demonstrate that human
shMASP-3 (hu shMASP-3) RNA can be used to silence MASP-3
in human cells expressing high levels of MASP-3. Our second
objective in this study was to generate a GalNAc–MASP-3–siRNA
duplex targeting the liver andto test its eﬃcacy in vivo inmicewith
andwithout arthritis. Our hypothesis is that liver-derivedMASP-3
is essential for the development of joint damage and that its
targeted hepatic inhibition can lead to the attenuation of arthritis.
MATERIALS AND METHODS
Determining the expression of MASP-3 in human cell lines
and in mouse and human liver
The human glioblastoma multiforme brain tumor cell line T98G
and the human liver carcinoma cell line HepG2 were grown in
Eagle’s MEM (Invitrogen by Thermo Fisher Scientiﬁc, Carlsbad,
CA) containing 5% FBS (HyClone, Logan, UT) and maintained at
37°C in 5% CO2 (44). Liver from WT C57BL/6 mouse was
dissected, washed in 13 PBS, and used to make the RNA. Total
RNA from the normal human liver was obtained from outside
sources as a residual material. Total RNA was extracted from
the human cell lines or from the mouse liver using the Qiagen
RNeasy Kit. RNA quality was validated prior to use by agarose
gel electrophoresis. Human or mouse MASP-1, MASP-2, and
MASP-3 expression in cells and in liver were determined by
quantitative RT-PCR (qRT-PCR) as described previously
(5, 45). Primer sequences used for ampliﬁcation of human or
mouse MASP-1–, MASP-2–, and MASP-3–encoding RNA are
available on request from the authors. Standard curves to calculate
the expression of MASP-1, MASP-2, and MASP-3 were made
using RNA from theHepG2, T98G cell lines,WTmouse liver, and
from the human liver.
RT-PCR for MASP-1, MASP-2, and MASP-3 expression in
cells and in liver
T98G or HepG2 cells or mouse liver tissues were lysed, and total
RNAwas prepared using RNeasyMini Kit (Qiagen, Germantown,
MD). Absence of RNA degradation was assessed by using a 1%
agarose gel, and cDNA was prepared (5, 45). MASP-1, MASP-2,
and MASP-3 mRNA were measured by RT-PCR. Quantitation
of 18S rRNA (18S rRNA) was used as an internal control in
each experiment, and all data were expressed in picograms per
nanogram mRNA/18S rRNA. All mRNA samples were analyzed
in duplicate. Samples were analyzed by amplifying at 40 cycles
according to themethodspublishedpreviously inNatureProtocols
(5, 45). All qRT-PCR data were analyzed by using cDNA based on
the standard curvemadebyusing liverRNA fromahealthy human
subject or normal WT mice.
Generating hu shMASP-3 RNA and shScramble RNA
vesicular stomatitis virus lentivirus particles and
transduction of human cells
hu shMASP-3 RNA targeting human MASP-3 (NM_139125.3)
(mission TRCN0000429394; Sigma-Aldrich, St. Louis, MO) and
shScramble RNA (mission pLKO.1-CMV-puro, SHC002; Sigma-
Aldrich) were obtained from the Functional Genomic Core of
the University of Colorado at Denver.
hu shScramble RNA was used as a negative control in each
experiment. The human embryonic kidney 293 cells transformed
with theSV40 largeTAg (HEK293T)packaging cell linewasused to
packagehushMASP-3RNAand togenerate lentivirus viral particles.
Brieﬂy, 2mg of shMASP-3 plasmidwas combinedwith 2mg of pack-
aging vector (3:1 M ratio of pD8.9 and pCMV-VSV-G at 100 ng/ml),
diluted in 400 ml of Opti-MEM (31985070; Life Technologies), and
incubated with 12 ml of 1 mg/ml polyethylenimine (Polysciences,
Warrington, PA) for 15–20 min at room temperature. The entire
contents of the tube were added to HEK293FT cells and incubated
overnight. After transfection for 16 h, the media on the cells were
replaced with complete DMEM. Forty-eight hours later, the
media containing viral particles were collected from transfected
HEK293FTcells, transferred to a 5-ml syringe, andﬁltered through
a 0.45-mM cellulose acetate ﬁlter (VWR, Radnor, PA), and used
immediately.
Transduction eﬃciency was established at various time points
using GFP-expressing viral particles, TurboGFP (SHC003; Sigma-
Aldrich). A total of 33 106 T98G or HepG2 cells per well (12-well
plate) were infected with 1.63 103 infectious units (16-ml volume)
of lentivirus particles expressing either shMASP-3 RNA or
shScramble RNA. After 24 h, viral media were replaced with
media containing puromycin (10 mg/ml).
To explore the short-term (at day 15) or the long-term (at
day 60) eﬀect of hu shMASP-3 RNA on MASP-3 silencing,
the following in vitro experiments were conducted. In the ﬁrst
experiment to examine the expression of MASP-3 in T98G or
HepG2 cells, after transfection with shMASP-3 RNA or shScram-
ble RNA, cells were harvested and lysed to make the total RNA at
day 15. To further explore the extended long-term eﬀect of hu
shMASP-3 RNA or of hu shScramble RNA on MASP-3 protein
at day 60, MASP-3 expression in T98G cell lysates was assessed
by qRT-PCR. We have not used HepG2 cells to show the longer-
term eﬀect at day 60 because of the longer-term toxicity of hu
shMASP-3 in this particular cell line.
https://doi.org/10.4049/immunohorizons.1800053
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Source of human and mouse serum lacking MASP-1/3
or MASP-2
Normal human serum and FD-depleted sera were obtained from
Complement Technology, Tyler, TX. Human and mouse serum
samples were stored at 270°C and were thawed only one time
prior to use.Human serumdeﬁcient inMASP-2 andMASP-1/3 for
these studies were kindly provided by Dr. P. Garred (Copenhagen,
Demark) and Dr. S. Thiel (Aarhus, Denmark), respectively. We
have established a colony of FD2/2,MASP-1/32/2, andMASP-22/2
miceonC57BL/6background.Sera fromWT,FD2/2,MASP-1/32/2,
and MASP-22/2 mice were obtained through retro-orbital
bleeding according to the approved protocol by the Institu-
tional Animal Care and Use Committee. All mice used in this
study were on C57BL/6 background. WT C57BL/6 mice were
also purchased from The Jackson Laboratory to obtain serum
for various studies. All mice were kept in our barrier facility
and fed breeder chow provided by the Center for Labora-
tory Animal Care, University of Colorado Anschutz Medical
Campus.
Analysis for ProFD and FD of mouse and human serum
deﬁcient in MASP-1/3 and MASP-2 proteins
The presence or absence of ProFD and FD was detected by
Western blotting of mouse and human serum deﬁcient in either
MASP-1/3 orMASP-2. Sera fromFD2/2mice andalso human sera
depleted in FD were also examined, which served as negative
controls. Normal sera fromWTC57BL/6mice and normal human
sera were used as positive controls in all experiments. Before
Western blotting, human serum (25 ml) was preincubated with
aﬃnity-puriﬁed goat anti-human FD (2 ml) (R&D Systems,
Minneapolis, MN), allowing ProFD and FD to be immunopreci-
pitatedwith ProteinA/G beads (12ml) (Santa Cruz Biotechnology,
Dallas, TX). The immunoprecipitates were then treated with
peptide-N-glycosidase F (PNGase F) overnight at 37°C according
to the manufacturer’s suggested protocol (New England BioLabs,
Ipswich, MA). The samples were analyzed by SDS-PAGE and
Western blot. After transfer, the blots were incubated for 1 h with
biotinylatedanti-human anti-FDAbas an alternativeAb that binds
to a diﬀerent epitope than the primary anti-human FD Ab used
for precipitation (dilution 1:500) (R&D Systems). Finally, the
proFD and FD bands at;26 kDawere detected using streptavidin
HRP conjugate (dilution 1:1000) (R&D Systems) and luminescent
substrate. The band of proFD was visually slightly bigger in kDa
than the FD band, and these diﬀerences were only visible by using
12% Bis-Tris Gel (14, 22, 28).
In vivo AP activation in MASP-1/32/2 mice by
recombinant MASP-3
To examine the cleavage of ProFD by rMASP-3 in vivo in
MASP-1/32/2mice, (male and female) were injected only once
i.v. in the tail with active or inactive rMASP-3 (serine changed to
alanine) (50 mg/mouse). After 24 h of injection with rMASP-3
protein, sera from allMASP-1/32/2 (n = 4) male and female mice
were examined ex vivo for AP activation. The AP activation in
serum at various dilutions (1:6 and 1:12 in EGTA/Mg buﬀer) was
determined by rabbit erythrocyte lysis analysis as described
earlier (32). Serum fromaWTcontrolmicewas used as a positive
control at various dilutions (1:6, 1:12, 1:24, and 1:48 in EGTA/Mg
buﬀer) in duplicate to show the speciﬁcity of rabbit erythrocyte
lysis for AP activation. The absorbance was read at 405 nm.
The serum samples before and after treatments with rMASP-3
were also analyzed for the cleavage of proFD intomature FDusing
Western blot analysis.
In vitro selection of active GalNAc–siRNA–MASP-3
duplexes
Fiftymouse siRNAsequencesweredesignedbasedon theavailable
bioinformatics information to target the MASP3 splice variant
of the MASP1 gene. GalNAc-siRNA conjugates were synthesized
using solid-phase synthesis methods as previously described (46).
Cos-7 cell line was used to examine the eﬀect of MASP-3 siRNA
duplexes on the expression of MASP-3 in vitro. A customized
fusion psiCHECK vector (Blue Heron Biotech, Bothell, WA) of
luciferase reporter gene andmouseMASP3was dilutedwithOpti-
MEM for a ﬁnal concentration of 1.2 ng/ml. MASP-3–siRNA and
control siRNAs were diluted eight times at a 6-fold serial dilution
beginning at 10 nM. The siRNA dilutions were cotransfected with
the psiCHECK vector (1:1 ratio) and preincubated for 15 min with
Lipofectamine (1:10 ratio) (InvitrogenbyThermoFisherScientiﬁc,
Waltham, MA). The cell suspension was added to each well
with the lipid/siRNA mix and incubated for 48 h at 37°C in an
atmosphere of 5% CO2. Dual-Glo Reagent (Promega, Madison,
WI)wasusedas the luminescenceaccording to themanufacturer’s
protocol and measured using Biotek Synergy HT plate reader.
Each data point was tested with at least four biological replicates.
Renilla luciferase reporter was used as the positive control. The
magnitude of siRNA activity was then normalized relative to
the negative control (psiCHECK2-MASP3 transfected but either
nontargeting siRNA or PBS). All transfections were done at n = 2
or greater.
psiCHECK2 Dual-Glo luciferase in vitro assay for MASP-3
gene silencing
The psiCHECK2 Dual-Glo system enables detection of siRNA-
mediated silencing of target sequences fused to aRenilla luciferase
reporter. The sequence of interest (MASP-3) was cloned into the
multiple cloning region (XhoI-NotI sites) located downstream of
the Renilla STOP codon in the 39UTR. RNAi-mediated cleavage
and degradation of the fusion mRNA can be measured by a loss in
Renilla signal following siRNA treatment. The psiCHECK2 vector
also contains a second reporter, ﬁreﬂy luciferase, which is driven
by a diﬀerent promoter and allows for normalization of Renilla
expression. When MASP-3 siRNAs are transfected in Cos-7 cells
followedby silencingofMASP3 gene, the levels of luciferase signal
also godown. IC50 of eachMASP-3duplexwas calculated from the
expression curve. The IC50 value has been listed for eachMASP-3
duplex on the plots. For example, duplex 4 (IC50 = 1.2 pM) is the
more eﬀective, as lower concentration of the duplex is enough to
silenceMASP-3expressionby50%,whereasduplex1 (IC50=41.2pM)
is less eﬀective in comparison.
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In vivo selection of active GalNAc–MASP-
3–siRNA duplexes
The eﬀect of MASP-3 siRNA by duplex 1 (duplex 3) and duplex 2
(duplex 4) was initially characterized in 8-wk-old naive C57BL/6J
mice (Charles River Laboratories), and later on, these duplexes
were further chemically modiﬁed. Single 1 or 10 mg/kg doses of
duplex 1 andduplex 2were administered s.c. Liverswere collected
on day 7 postinjection. ThemRNAwas isolated using RNeasy Plus
Mini Kit (Qiagen). High-Capacity cDNA Reverse Transcription
Kit (Thermo Fisher Scientiﬁc) was used to convert the mRNA
samples. Levels of MASP3 expression were analyzed using
qRT-PCR reagents compatible with Roche Lightcycler 480. The
MASP3 mRNA was measured using a customized TaqMan assay
(Thermo Fisher Scientiﬁc) and normalized to the endogenous
GAPDH expression (Thermo Fisher Scientiﬁc).
In another experiment, C57BL/6J mice were injected with
duplex 1 or with duplex 2 on day25, day 0, and day 3 followed by
liver collection at day 10, as thiswould be a relevant time point in a
CAIA model (see below). Serum was obtained prior to injections
to examine the levels of circulating MASP-3 by Western blot and
ELISA. Liver was collected on day 10 and examined for MASP-3
expression using qRT-PCR.
Lastly, WT mice (n = 10) were injected with GalNAc–
luciferase–siRNA or with duplex 2 of GalNAc–MASP-3–siRNA
on day 210, day 0, and day 3. Sera from mice were obtained
prior to injections to examine the circulating levels of MASP-3
protein byWestern blot and ELISA. Liver was collected on day
10 and tested for MASP-3 mRNA expression using qRT-PCR.
The impact of GalNAc–MASP-3–siRNA duplexes on MASP-1
levels was tested by examining the serum for MASP-1 levels
by ELISA.
Western blot analysis for human MASP-3 in T98G cell
supernatants following MASP-3–encoding mRNA
knockdown by shRNA and for MASP-1 and MASP-3 from
mouse serum following siRNA treatment
InfectedandcontrolT98Gcell culture supernatants atday60were
collected and concentrated by centrifuging in Centricon Plus-70
Filter Units at 3000 rpm for 30 min (Millipore, Bedford, MA).
MBL/MASP-1 or MBL/MASP-3 complexes were pulled out by
incubating 20 ml of concentrated supernatant with 20 ml of
mannan-agarose (Sigma-Aldrich) at 4°C overnight. The beads
were washed and then subjected to 4–12% Tris-Glycine Gel
(Invitrogen by Thermo Fisher Scientiﬁc) SDS-PAGE. Similarly,
to analyze the eﬀect of GalNAc–luciferase–siRNA or GalNAc–
MASP-3–siRNA on MASP-3 in vivo, 20 ml of serum from each
mouse was incubated with mannan-agarose as described above.
All sampleswere transferred to0.2mmofmicroporous Immobilon
PSQ Transfer Membrane, polyvinylidene diﬂuoride (PVDF)
membrane (7 cm3 8.4 cm size) (MerckMillipore, Tullagreen,
Carrigtwohill, County Cork, Ireland) using Tris-Glycine Transfer
Buﬀer (Invitrogen by Thermo Fisher Scientiﬁc) for 1 h at 100 V.
The PVDF membrane was blocked in 5% dry milk in 13 PBS
containing 0.05% Tween 20 for 1.5 h and incubated overnight
at 4°C with either 1) human anti–MASP-3 primary Ab (1:200
dilution) (Santa Cruz Biotechnology) 5% dry milk for analysis of
humanMASP-3 derived fromT98G cells or 2) rabbit anti–MASP-
3 primary Ab at a 1:200 dilution (produced in-house at Dr. Thiel’s
laboratory) in5%drymilk for analysis ofMASP-3 inmouseserum.
All blots were washed 3 times in 13 PBS containing 0.5%
Tween 20 then incubated with either 1) HRP-conjugated goat
anti-mouse (1:5000 dilution) (Santa Cruz Biotechnology) or 2)
HRP-conjugated goat anti-rabbit (1:5000) (Jackson Immuno-
Research, West Grove, PA) diluted in 5% milk containing
0.5% Tween 20.
Finally, themembraneswere developed from 1 to 5min using a
1:1mixture of SuperSignalWest PicoChemiluminescent Substrate
(ThermoFisherScientiﬁc).Diﬀerent concentrationsofa truncated
formof the recombinant humanMASP-3proteinwere alsoused as
a positive control alongwith normal human serum.Theblotswere
FIGURE 1. Comparing level of MASP-1, MASP-2, and MASP-3
expression by qRT-PCR in human liver and brain cell lines and in
human and mouse liver.
(A) HepG2 and T98G cell lines (B). Comparing the MASP-1, MASP-2, and
MASP-3 expression in the liver from mouse and human. The mRNA ex-
pression data shown in this study for MASP-1, MASP-2, and MASP-3 were
repeated three times for human and mouse liver. Data are shown as
mean6 SEM of three replicates. The p values were calculated using t test.
*The p values ,0.05 were compared between T98G and HepG2 cell
lines and also between human and mouse liver as shown in the graphs.
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scanned using GeneGnome XRQ Chemiluminescence Imaging
SystemandGeneTools analysis software fromSyngene(Frederick,
MD), and the density of each band was quantiﬁed using the
Quantity One software (Bio-Rad, Hercules, CA).
The procedure for measuring MASP-1 was identical to that
described above. The PVDF membrane was blocked and then
probed with rabbit anti–MASP-1 primary Ab (1:200) in 5% dry
milk. Sera fromWT andMASP-1/32/2mice were used as positive
and negative controls, respectively.
Assay to measure MASP-3 protein by time-resolved
immunoﬂuorometric immunoassay in the circulation
Serum samples from various cohorts fromWTC57BL/6micewith
no disease or with CAIA injected s.c. with GalNAc–luciferase–
siRNA or with duplex 1 or with duplex 2 of GalNAc–MASP-
3–siRNAwere analyzed by time-resolved immunoﬂuorometric
immunoassays as previously described (26, 32, 47) by using in-
house Abs. Sera were diluted 1:50 to measure the levels of
MASP-3 in mouse serum. For MASP-3, sera from WT and
FIGURE 2. Long-term effect of the lentiviral vector–mediated RNAi by qRT-PCR on MASP-1, MASP-2, and MASP-3 expression in vitro in human
T98G and HepG2 cells.
T98G or HepG2 cells were either untreated (cell alone) or transfected with shRNA lentivirus carrying no-target control shScramble RNA (NT Ctrl
shRNA) or with MASP-3–specific shRNA lentivirus (shMASP-3 RNA) particles. (A) MASP-1 expression in T98G cells. (B) MASP-2 expression in T98G
cells. (C) MASP-3 expression in T98G cells. (D) MASP-1 expression in HepG2 cells. (E) MASP-2 expression in HepG2 cells. (F) MASP-3 expression in
HepG2 cells. 18S rRNA was used an internal control. Data are shown as mean6 SEM of three replicates. The p values were calculated using ANOVA.
*p , 0.05 versus with the cells alone or NT Ctrl shRNA or shMASP-3 RNA.
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MASP-1/32/2micewere used as positive and negative controls,
respectively.
Effect of GalNAc–MASP-3–siRNA on induction of CAIA
in mice
WTmice were injected s.c. with 10mg/kg on days210, -5, and on
day 0 either with GalNAc–luciferase–siRNA (n = 22) or GalNAc–
MASP-3–siRNA (duplex 2) (n = 22). Then, CAIA was induced in
WTmice by using amixture of ﬁvemAb to bovine collagen type II
(Arthrogen-CIA, Chondrex) resuspended in sterile Dulbecco’s
PBS according to our previously published studies (13, 15, 34, 48).
All WT mice received i.p. injections of 8 mg of Arthrogen on day
0 and 50mg of LPS fromEscherichia coli strain 0111B4 on day 3. All
mice were sacriﬁced at day 10 post–LPS injection. The total
duration of the CAIA experiment was day 20 after the ﬁrst
siRNA injection. The severity of clinical disease activity (CDA)
in all groups of WT mice was determined every day by two
trained laboratory personnel acting independently and blindly
according to our previously published study (4). The in vivo
CAIA experiments were repeated three times (total n = 44)
using an identical dose of duplexes and an identical injection
schedule.
Assessment of histopathology, C3 deposition, and
macrophage in joints
At day 10, both forepaws and the entire right hind limb, including
the paw, ankle, and knee were surgically removed and ﬁxed
immediately in 10% buﬀered formalin (Biochemical Sciences).
The preparation of knee joint samples and histological analysis
using toluidine blue (T blue) dye were performed as previously
described (14, 15). All sectionswere readby a trainedobserverwho
was also blinded to the treatment and to the disease activity score
of each mouse. The joint sections from mice were scored for the
changes in inﬂammation, pannus, cartilage damage, and bone
damage on a scale of 0–5. C3 deposition in the joints (synovium
and cartilage) was localized with polyclonal goat anti-mouse
C3 antisera (ICN Pharmaceuticals) and scored as previously
described (13).Macrophages inﬁltration in the knee jointswere
localized with rat anti-mouse F4/80 Ab (Bio-Rad) and scored
using a scale from 0 to 4.
Immunohistochemical localization of MASP-3 protein in
the joints of mice
All joints from one CAIA experiment (n = 14) used for
histopathology studies after treatments with GalNAc–luciferase–
siRNA or GalNAc–MASP-3–siRNA described above were col-
lected for further immunohistochemical (IHC) localization of
MASP-3 protein. All ﬁve joints (i.e., both forelimbs and the right
hind limb) (knee joint, ankle, and hind paw) were processed for
IHCstudies and for theMASP-3deposition in the joints. Liverand
brain fromWTwere used as positive controls, whereas liver from
MASP-1/32/2 mice was used as negative control. Five micron–
thick paraﬃn sections were prepared for immunodetection and
stained with rabbit anti-mouse MASP-3 biotinylated Ab at a
dilution of 1:200. Sections required modest retrieval in 10 mM
sodium citrate pH 6 for 10 min at 110°C in the NxGen Decloaker
(BiocareMedical,Concord,CA)with a 10mincooldown.MASP-3
immunodetection was performed on the Benchmark XT autos-
tainer (Ventana Medical Systems, Tucson, AZ) at an operating
temperature of 37°C with primary incubation for 32 min using a
modiﬁed iVIEW DAB (Ventana Medical Systems) Detection Kit.
The iVIEW secondary Ab was replaced with full-strength Rabbit
ImmPRESS polymer (Vector Laboratories, Carpinteria, CA), and
the enzymewas replacedwith dilutedRabbit ImmPRESSpolymer
FIGURE 3. Western blot analysis for proFD or FD of human and mouse serum lacking MASP-1/3 and MASP-2 genes.
(A) Sera from MASP-1/32/2mice contain only proFD (lane 2) versus sera from MASP-22/2mice, which contain FD (lane 3). Sera from FD2/2 (lane 1)
and WT (lane 4) mice were used as a negative and positive controls, respectively. (B) Sera from human deficient in MASP-1/3 contain only proFD
(lane 2) versus sera from human lackingMASP-22/2, which contains FD (lane 3). Human sera depleted of FD (lane 1) were used as a negative control.
These Western blot experiments were repeated three times.
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(Vector; 50% v/v in PBS pH 7.6). All sections were counterstained
in hematoxylin for 2 min, blued in 1% ammonium hydroxide,
dehydrated in graded alcohols, cleared in xylene, and cover glass
mounted using synthetic resin. Negative controls to conﬁrm
the speciﬁcity of the immunostaining included omission of
the primary Ab incubation step in the IHCprotocol, substitution
of the primary Ab diluent. Because of the overall low deposition
of MASP-3 in the joints, an ordinal scale was used to assess
levels.
Statistics
All data were analyzed using GraphPad Prism 4.0 program.
The CDA data from all individual WT mice were included
in the ﬁnal analysis of histolopathology and immunohisto-
chemistry. The density of bands from Western blots was
determined by using Bio-Rad Quantity One program after
scanning and subtracting the background from blots. To
analyze mRNA data from T98G or HepG2 cells and in mouse
and human liver, t test was used. The test of ANOVA was used
to ﬁnd the statistical diﬀerences comparing more than three
independent treatment groups. All data were expressed as the
mean6 SEMwith p,0.05 considered signiﬁcant, and original
p values have been shown.
RESULTS
Expression of MASPs in different human cell lines, in
mouse, and in human liver
Weexamined twohumancell lines (i.e., T98GandHepG2 forMASP
mRNA expression). Overall, human HepG2 liver cells expressed
MASP-1, MASP-2, andMASP-3, and T98G cells expressedMASP-1
andMASP-3butnodetectableMASP-2 (Fig. 1A).Humanandmouse
liver expressed all three mRNAs (Fig. 1B). Human liver HepG2
and brain T98G cells expressedmoreMASP-3 thanMASP-1mRNA
(Fig. 1A). Mouse liver tissue showed signiﬁcant (p = 0.05) higher
expression levels of all MASP mRNAs (i.e., MASP-1, MASP-2, and
MASP-3 expression) compared with the human liver (Fig. 1B).
FIGURE 4. In vivo reconstitution of AP activity in MASP-1/32/2 mice with rMASP-3.
An ex vivo assessment of the AP by lysis of rabbit blood erythrocytes (RBEs) and cleavage of proDF by Western blot analysis at 24 h from MASP-
1/32/2–injected mice with active (rM3) or inactive or mutated rM3 (rM3 S/A). (A) Natural RBEs lysis by WT serum using various dilutions as expected. (B)
No RBEs lysis by MASP-1/32/2 mouse serum reconstituted with rM3 S/A. (C) RBEs lysis by MASP-1/32/2 serum reconstituted with rM3. (D) Western
blot showing the cleavage of proFD into FD only after injecting rM3, not rM3 S/A (lane 7 versus lane 5). Data fromMASP-1/32/2mice shown (B and C)
as mean OD6 SEM. All samples were run in duplicate with highly reproducible data from twoMASP-1/32/2male and two female mice. Western blot
were repeated three times. M1/3 + rM3, MASP-1/32/2 mice treated active rMASP-3; M1/3 + rM3 S/A, MASP-1/32/2 mice treated inactive rMASP-3;
dil, serum dilutions; Tx, treatment.
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We used both HepG2 and T98G cells to test our ability to decrease
humanMASP-3 mRNA expression in a speciﬁc fashion.
hu shMASP-3 RNA speciﬁcally decreases the expression of
MASP-3 in human HepG2 and T98G cells
Lentiviruses expressing either GFP, hu shMASP-3 RNA, or
a control hu shScramble RNA were prepared as described in
Materials and Methods. Eﬃciency of infection was ﬁrst qualita-
tively assessed using GFP expression. Lentiviral particles consist-
ing of a mixture of GFP and either hu shMASP-3 RNA or control
shRNA were incubated with HepG2 or T98G cells for 24 h
followedbywashingand feedingwith freshmedia. Puromycinwas
added to the media to select for infected cells. GFP expression
wasvisualized aftereither24hor 15d inT98Gcells (Supplemental
Fig. 1). The percentage of T98G cells expressing GFP increased
with lentiviral doses of 0.2, 0.4, and 1.6 3 103 particles (data not
shown). For this reason, all subsequent experiments in this series
were performed with 1.6 3 103 particles using HepG2 or T98G
cells. After lentiviral infection, day 15 cultures from HepG2 and
T98G were then examined for expression of MASP-1, MASP-2,
and MASP-3 mRNA. Cultures were lysed, total RNA puriﬁed,
and MASP mRNA levels measured as described inMaterials and
Methods. MASP-1, an alternative splice variant of the MASP-1/3
gene, was unaﬀected by infectionwith either control or shMASP-
3 RNA lentiviruses (Fig. 2A, 2D). Similarly, MASP-2 gene ex-
pression was unaﬀected in HepG2 cells (Fig. 2E), but the direct
FIGURE 5. IC50s for MASP3 silencing with GalNAc-MASP3 siRNAs: Dual-Glo luciferase assay was performed using Cos7 cells expressing a firefly
luciferase–MASP3 fusion construct.
Cells were transfected with mouse MASP3-specific siRNAs at the concentrations indicated. Luminescence levels were measured at 48 h post-
transfection. The ratio of normalized luminescence was plotted in Microsoft Excel to calculate the IC50 for each duplex. (A) Duplex 1 IC50 = 41.2 pM.
(B) Duplex 2 IC50 = 4.6 pM. (C) Duplex 3 IC50 = 34.4 pM. (D) Duplex 4 IC50 = 1.2 pM. Duplex 1 = duplex 3 and duplex 2 = duplex 4. These experiments
were repeated two times with each new duplex with highly reproducible results, and data are shown as mean 6 SEM. IC50, half maximum inhibitory
concentration.
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eﬀect of shMASP-3 RNA could not be determined on T98G
cells, for these cells expressed very lowor undetectableMASP-2
(Fig. 2B). InHepG2 cells, therewas a signiﬁcant (p, 0.001) 70%
decrease at day 15 in the expression of MASP-3 by hu shMASP-3
RNA compared with cells alone or control Scramble shRNA (Fig.
2F). In striking contrast, inT98Gcells, shMASP-3RNA–expressing
lentiviruses (but not the control lentivirus) caused the level of
MASP-3mRNAtodropby95%(Fig. 2C).Nofurtherdecrease in the
expression ofMASP-3was seen by using higher doses of lentivirus
(data not shown). These data show that human MASP-3 can be
silenced speciﬁcally by using hu shMASP-3 RNA in human cell
lines without signiﬁcantly aﬀecting the expression of MASP-1 or
MASP-2, if these are present.
hu shMASP-3 RNA attenuated the MASP-3 protein levels in
the T98G cell supernatants
To establish the durability of shMASP-3 RNA infection, T98G
cells were incubatedwith lentiviral particles, washed, and cul-
tured for 60 d. Supernatants were then collected, concentrated
and examined for MASP-3 protein using Western blot analy-
sis (Supplemental Fig. 2). There was an almost complete lack of
MASP-3 protein in the supernatants of T98G cells at day 60
(Supplemental Fig. 2A, lane 5) comparedwith the cells transfected
with shScramble RNA (Supplemental Fig. 2A, lane 4). Puriﬁed
recombinant human MASP-3 catalytic fragment in varying
amounts was used as a positive control (Supplemental Fig. 2B,
lanes 2–5). These Western blot data show that hu shMASP-3
RNA speciﬁcally targeted human MASP-3 in T98G cells and
reduced its expression substantially after 2 mo in culture.
Presence of ProFD in the sera from both MASP-1/32/2 mice
and MASP-1/3–deﬁcient humans
To explore the role ofMASP-3 in the cleavage of proDF tomature
FD, we examined sera from both mice and humans deﬁcient in
the alternatively spliced MASP-1/3 gene by immunoprecipitation
followed by Western blot analysis (Fig. 3). We found that both
mouse and human serum contained only ProFD in the complete
absenceofMASP-1/3 (Fig. 3A, lane2, andFig. 3B, lane2). In contrast,
no proFD but only FD was present in human sera with MASP-2
deﬁciency (Fig. 3, lane 3). Serum from MASP-22/2-deﬁcient
mice also contained FD, but did not contain proFD (Fig. 3, lane 2).
Sera from FD2/2 were used as a negative control, and no band
of either FD or proFD is present (Fig. 3A, lane 1, and Fig. 3B,
lane 1).
In vivo recombinant MASP-3 activated AP and cleaved
proFD in MASP-1/32/2 mice
To determine the requirement of MASP-3 in vivo to reconsti-
tute the AP, MASP-1/32/2 mice were injected with an active
recombinant MASP-3 (rM3) or with an inactive or mutated rM3
(rM3S/A), andAPactivitywas examinedafter 24hbywell-known
rabbit erythrocyte lysis assay speciﬁc formeasuring theAPactivity
(32). AP is normally compromised in MASP-1/32/2 mice versus
WTmice because of proFD presence in their circulation (Fig. 4A,
4B). Exogenous active rMASP-3 compared with the mutated
rMASP-3 clearly reconstituted the AP activity in the sera from
MASP-1/32/2mice at 24h (Fig. 4C). The ex vivoAPactivity in sera
fromMASP-1/32/2mice after reconstitutionwas equivalent to the
WTmouse serum (Fig. 4A, 4C). There were no diﬀerences in the
ability of active rM3 to reconstitute the AP activity both in male
and female mice (Fig. 4C). Furthermore, at 24 h, exogenous rM3
not only activated the AP but also cleaved the proDF in vivo in
MASP-1/32/2mice (Fig. 4D, lane 7 versus lane 5). Thesedata show
that MASP-3 is speciﬁcally required for the cleavage of proDF
into DF in vivo and results in the subsequent capacity for AP
activation.
In vitro identiﬁcation of GalNAc–MASP-3–siRNA duplexes
Mouse-speciﬁc siRNA sequences were identiﬁed using Alnylam
bioinformatic tools. Chemically stabilized duplexes conjugated to
a triantennary GalNAc on the 39 end of the sense strand were
synthesized using solid-phase synthesis methods (46). MASP-
3–siRNAs were tested in vitro using a psiCHECK vector
expressing MASP3 gene in Cos-7 cells. The silencing of MASP-3
was examined based on the inhibition of luciferase activity
following transduction with various GalNAc–MASP-3–siRNA
duplexes. Four duplexes show IC50 silencing of 41.2, 4.6, 34.4,
and 36 pM, respectively (Fig. 5).
GalNAc–MASP-3–siRNA duplex silenced MASP-3
expression in mice with no disease
Three independent in vivo experiments were done to determine
the eﬃciency of GalNAc–luciferase–siRNA or GalNAc–MASP-
3–siRNA duplexes on the expression of MASP-3. In the ﬁrst
experiment, to examine the short-termeﬀect ofGalNAc–MASP-3,
FIGURE 6. Semiquantitative RT-PCR analysis of MASP-3 expression
from the liver of WT mice injected with GalNAc–MASP-3–siRNA
duplexes.
Total RNA was extracted at day 7 from the liver of mice injected s.c. with
two different doses of GalNAc–MASP-3–siRNA duplexes. MASP-3 ex-
pression was examined using qRT-PCR. Liver from WT mouse was used
as a positive control to make a standard curve (data not shown). 18s
RNA was used as an internal control to calculate the expression of
MASP-3 (pg/18s RNA). Data shown as mean 6 SEM of three replicates.
Empty bars = 1 mg/kg and solid black bars = 10 mg/kg. The p values
were calculated using t test. *p , 0.05 versus PBS.
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WT mice (n = 15) were injected s.c. with a single dose of either
PBS or GalNAc–MASP-3 duplexes 1 or 2 at day 0 and sacriﬁced
at day 7 (Fig. 6). Duplex 2 was most eﬀective at blockingMASP-3
at both 1 and 10 mg/kg doses. Both duplexes have no eﬀect on
the expression of MAp44 (Supplemental Fig. 3A) and MASP-1
(Supplemental Fig. 3B).
In the second experiment, to examine the long-term eﬀect of
GalNAc–MASP-3–siRNA,WTmice (n = 6)were injected s.c. three
times either with GalNAc–luciferase–siRNA or GalNAc–MASP-
3–siRNA duplexes 1 or 2 at day –5, at day 0, and at day 3. Themice
were then sacriﬁced at day 10 (Fig. 7). ELISA results conﬁrmed
that at day 10, therewas adecrease in the levels ofMASP-3protein,
which ranged from 54 to 64% of control in mice injected with
GalNAc–MASP-3–siRNAduplex 2 (Fig. 7A). A standard curvewas
generated after reconstituting the sera from MASP-1/32/2 mice
with known quantities of rM3 to show the speciﬁcity of MASP-3
ELISA (Fig. 7B). Sera from these mice were also analyzed by
Western blot, conﬁrming decreases in the range of 60% as
measured by densitometric analysis (Fig. 7C, lane 7). Addition-
ally, duplexes 1 and 2 caused a marked decrease in liverMASP-3
mRNA abundance by day 10 as compared with control (Fig. 7D).
In the third experiment, WTmice (n = 15) were injected three
times with GalNAc–luciferase–siRNA or GalNAc–MASP-3–
siRNAs duplex 1 or duplex 2 at day –10, day 0, and at day 3
followed by sacriﬁcing all mice at day 10 (Fig. 8). In this fashion,
the time between ﬁrst and second doses was extended from 5 to
10 d. Serum MASP-3 dropped by ;15% by day 10 (p = 0.015) as
compared to the 60% drop seen in the previous experiment
(compareFigs. 7Aand8A).MASP-1protein levelswerecompletely
unaﬀected (Fig. 8B). Sera from mice injected with duplex 2 were
FIGURE 7. A short-term comparison of the in vivo efficiency of GalNAc–MASP-3–siRNA duplex 1 or GalNAc–MASP-3–siRNA duplex 2 in mice
with no CAIA.
(A) ELISA showing the levels of MASP-3 protein in the sera from six mice treated with GalNAc–luciferase–siRNA (n = 2) (mouse no. 1 and mouse no.
2) or GalNAc–MASP-3–siRNA no. 1 (mouse no. 3 and mouse no. 4) or GalNAc–MASP-3–siRNA no. 2 duplexes (mouse no. 5 and mouse no. 6). (B) A
standard curve showing the specificity of MASP-3 protein ELISA using serum from a MASP-1/3–deficient mouse reconstituted with various doses of
active recombinant mouse MASP-3 (250, 50, 10, and 2 ng/ml). (C) Western blot analysis for MASP-3 protein levels using sera from WT mice (mouse
no. 1 or mouse no. 6) injected with GalNAc–luciferase–siRNA or with GalNAc–MASP-3–siRNA no. 2 duplex, at day –5 (lanes 2 and 3), at day 0 (lanes
4 and 5), at day 3 (lanes 6 and 7), and at day 10 (lanes 8 and 9). Sera from MASP-1/32/2 mice with no injections of siRNAs were used as a negative
control (lane 1). Western blot data were repeated two times from mouse no. 1 and mouse no. 6. A band of MASP-3 protein (;94–100 kDa) in serum
shows its presence. (D) qRT-PCR showing the expression of MASP-3 in the liver at day 10 from WT mice injected with MASP-3 no. 1 or no. 2
duplexes. Western blots were replicated two times. Mean 6 SEM of three replicates. Error bars in the second and third bars are invisible because of
very low values in mice treated with GalNAc–MASP-3–siRNA duplexes no. 1 or 2. The p values were calculated using t test. *p , 0.05 comparing
Luc siRNA–treated mice with GalNAc–MASP-3–siRNA duplex 1–treated or duplex 2–treated mice. Luc, luciferase.
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also analyzed by Western blot (Fig. 8C). Densitometry measured
the decrease in MASP-3 to be 32.5% at day 10. Liver from mice
injectedwithduplex 1orduplex2ofGalNAc–MASP-3–siRNAalso
showed a 33.0% (p = 0.044) decrease in the expression ofMASP-3
after treatment (Fig. 8D). These short-term and long-term
experiments in healthy WT mice show that duplex 2 of GalNAc–
MASP-3–siRNA performed better compared with duplex 1;
therefore, we decided to use duplex 2 for CAIA study.
GalNAc–MASP-3–siRNA duplex partially attenuated
clinical disease in mice with CAIA
To examine the eﬃcacy of our GalNAc–MASP-3–siRNA duplex 2
for the treatment of RA, we employed the CAIA model in which
mice are injected with pathogenic anti-collagen Abs on day 0 and
then injected with LPS on day 3. Synovitis develops rapidly and
peaks by day 10. Mice are then sacriﬁced on day 10 for analysis.
In this experiment,WTmice (n = 22) were injected s.c. on day –10
before the inductionofdiseaseandagainonday–5andonday0with
either GalNAc–luciferase–siRNA or with GalNAc–MASP-3–siRNA
(duplex 2) (n = 22) as described inMaterials andMethods (Fig. 9).
CDA was assessed daily. Strikingly, initial disease progression in
theMASP-3 siRNAgroupwasmarkedly slowedas comparedwith
the luciferase siRNA–injected group until day 6 where the CDA
was decreased by 69% (p , 0.001). Between days 6 and 7, there
was a reproducible acceleration in disease in the MASP-3 siRNA
injection group followed by a general disease plateau for both
groups. By day 10, the average CDA for the luciferase siRNA–
injected group was 10.40 6 0.545, whereas the average CDA
for the MASP-3 siRNA–injected group was 5.13 6 0.798; thus, a
decrease of 50% was observed (p , 0.001) (Fig. 9A). In all three
FIGURE 8. A long-term comparison of the in vivo efficiency of GalNAc–MASP-3–siRNA duplex 1 or GalNAc–MASP-3–siRNA duplex 2 in mice
with no CAIA.
(A) ELISA showing a decrease in the levels of MASP-3 protein in the sera from mice treated with GalNAc–MASP-3–siRNA no. 1 or no. 2 duplex. (B)
ELISA showing no off-target effect on the levels of MASP-1 protein from mice injected with GalNAc–MASP-3–siRNA duplex 1 and GalNAc–MASP-
3–siRNA duplex no. 2 or GalNAc–luciferase–siRNA. (C) Western blot analysis for MASP-3 protein using sera from WT mice injected only with
GalNAc–MASP-3–siRNA duplex no. 2. MASP-3 protein in the sera from WT mice injected with GalNAc–uciferase–siRNA or GalNAc–MASP-3–siRNA
duplex no. 2, at day –10 (lanes 1 and 2), day 3 (lanes 3 and 4), and at day 10 (lanes 5 and 6). (D) qRT-PCR showing the expression of MASP-3 in the liver at
day 10 from mice injected with GalNAc–luciferase–siRNA or GalNAc–MASP-3–siRNA duplexes no. 1 or 2. 18s RNA was used as an internal control and to
calculate the expression of MASP-3 in the liver. Data from all mice have been included. The p values were calculated using t test. *p , 0.05 versus mice
injected with Luc siRNAs were compared using t test. Luc, luciferase.
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separate experiments, there was a consistent decrease in the
CDA in mice treated with MASP-3 siRNA. Individual CDA in
each mouse was also consistent with the overall decrease in the
CDA in mice treated with GalNAc–MASP-3–siRNA (data not
shown). The prevalence of disease at day 10 inWTmice injected
with GalNAc–luciferase–siRNA or GalNAc–MASP-3–siRNA
duplex 2 was 100 and 90%, respectively (Fig. 9B). There was a
signiﬁcant (p = 0.05) eﬀect on the weight of mice treated with
GalNAc–luciferase–siRNA or GalNAc–MASP-3–siRNA duplex 2
at day 0 and at day 10 (Fig. 9C). All mice survived to the ex-
perimental endpoint, and these in vivo CAIA were repeated three
times (n = 44) with almost similar results; data shown in this paper
are from all experiments. Overall, these data indicate that
GalNAc–MASP-3–siRNA duplex 2 partially inhibited the develop-
ment of CAIA in mice.
Decrease in the histopathology scores, C3 deposition, and
macrophages in the joints of mice treated
with GalNAc–MASP-3–siRNA
Joints derived from the CAIA experiments no. 1 (n = 14) out of
three experiments described above were collected for further
analysis. Allﬁve joints (i.e., both forelimbs and the right hind limb)
(knee joint, ankle and hind paw) were processed for histopathol-
ogy studies and for themeasurement of C3 deposition in the joints
(Fig. 10A). All data are shown as an all joint mean (AJM) score
(0–5). Histopathology scores for inﬂammation, pannus formation,
cartilage damage, bone damage show a 53% signiﬁcant (p = 0.006)
decrease (Fig. 10A). These data are consistent with the improve-
ment in CDA (Fig. 9A). There was a signiﬁcant decrease in
inﬂammation 45% (p = 0.007), pannus formation 53% (p = 0.006),
cartilage damage 55% (p = 0.0049) and bone damage 61%
(p = 0.0019) in CAIAmice treated with GalNAc–MASP-3–siRNA
duplex 2 compared with CAIA mice treated with GalNAc–
luciferase–siRNA (Fig. 10A). Representative pictures shown of
T blue staining related to histopathology from the knee joints
(Fig. 11A, 11B) and ankle (Fig. 11C, 11D) of mice treated with
GalNAc–MASP-3–siRNAduplex 2 orGalNAc–luciferase–siRNA.
Both the knee joints were examined for C3 deposition in the
synovium as well as on the surface of cartilage (Fig. 10B). All data
are shown as an AJM score (0–4) and also the total score (0–8).
Therewas a 35% (p = 0.031) and 37% (p = 0.017) decrease in the C3
deposition in the synovium and also on the surface of cartilage,
respectively (Fig. 10B), in mice treated with GalNAc–MASP-
3–siRNA duplex 2 (n = 7) compared with mice treated with
GalNAc-luciferase. These data are also consistent with the
decrease in CDA in mice treated with GalNAc–MASP-3 versus
GalNAc-luciferase (n = 7). Representative pictures shown of C3
deposition from the knee joints (Fig. 12A, 12B) of mice treated with
GalNAc–MASP-3–siRNA duplex 2 or GalNAc–luciferase–siRNA.
There was a nonsigniﬁcant 28% decrease (p = 0.39) in
macrophage inﬁltration in the synovium of knee joints of mice
with CAIA treated with GalNAc–MASP-3–siRNA duplex 2 com-
pared with mice treated with GalNAc-luciferase. Representative
pictures shown of macrophage staining from the knee joints (Fig.
13A, 13B)ofmicewithCAIA treatedwithGalNAc–MASP-3–siRNA
duplex 2 or GalNAc–luciferase–siRNA.
Decrease in MASP-3 protein deposition in the joints of mice
after treatments with GalNAc–MASP-3–siRNA
IHC analysis and images of MASP-3 protein in the joints of CAIA
mice treated with GalNAc–MASP-3–siRNA duplex 2 compared
FIGURE 9. CDA in WT mice treated with GalNAc–MASP-3–siRNA
duplex 2.
(A) CDA in mice treated with GalNAc–luciferase–siRNA or GalNAc–
MASP-3–siRNA. (B) Prevalence (%) of disease at day 10 in mice treated
with GalNAc–luciferase–siRNA or GalNAc–MASP-3–siRNA duplex 2. (C)
Change in weight (%) in mice treated with GalNAc–luciferase–siRNA or
GalNAc–MASP-3–siRNA duplex 2. Data shown represent the mean 6
SEM based on WT mice injected s.c. with GalNAc–luciferase–siRNA,
n = 22 and with GalNAc–MASP-3–siRNA duplex 2, n = 22. In vivo CAIA
experiments were repeated three separate times using total n = 44 (cohort 1
n = 14 mice, cohort 2 n = 14 mice, and cohort 3 n = 16 mice). The p values
were calculated using t test. *p , 0.05 in comparison with mice to
GalNAc–luciferase–siRNA–injected mice.
https://doi.org/10.4049/immunohorizons.1800053
286 TREATMENT OF ARTHRITIS WITH A MASP-3 RNAi THERAPEUTIC ImmunoHorizons
 by guest on M
ay 29, 2019
http://w
w
w
.im
m
unohorizons.org/
D
ow
nloaded from
 
with GalNAc–luciferase–siRNA showed lower levels of MASP-3
deposition in the knee joints synovium and forepaws synovium
(Fig. 14A–I). No deposition of MASP-3 was found in the cartilage
surface. Overall, the MASP-3 deposition was lower in the knee
joints compared with the forepaws of mice with disease (Fig.
14E–H). Interestingly,MASP-3 depositionwas also not seen in the
synovial ﬁbroblast-like cells but in diﬀerent cells, and the identity
of thesecells is unknownatpresent.Notably, theseMASP-3–positive
cells were also present in the vicinity of fat cells known to secrete
proFD(Fig. 14H).ForMASP-3 IHClocalization, liverandbrain from
WTwere used as positive controls (Fig. 14A–D), whereas liver from
MASP-1/32/2 mice was used as negative control (Fig. 14I). These
IHCdatashowthatMASP-3 ispresent in the joints,but itsdeposition
is low, and also it decreases with GalNAc–MASP-3–siRNA duplex 2
treatment in mice with CAIA (Fig. 14E–H).
GalNAc–MASP-3–siRNA duplex attenuated MASP-3
protein levels in the circulation of mice before and after the
development of disease
Sera from CAIA mice treated with GalNAc–MASP-3–siRNA or
withGalNAc–luciferase–siRNAwereanalyzedatday 10 forMASP-
3 protein using Western blot analysis (Fig. 15A). Overall, there
was a 47% decrease in the levels of MASP-3 protein, which,
interestingly, was consistent with the 50% decrease in CDA as
FIGURE 10. Histopathology scores and C3 deposition in CAIA mice injected s.c. with GalNAc–MASP-3–siRNA duplex 2 compared with
GalNAc–luciferase–siRNA.
All mice were sacrificed at day 10 and histopathology using T blue measured in AJM score at day 10. (A) AJM histopathology for inflammation,
pannus formation, cartilage damage, and bone damage. (B) Mean C3 deposition scores from both the knee joints in the synovium, on the surface of
cartilage, and total scores (synovium plus cartilage). All data represent the mean 6 SEM comparing GalNAc–luciferase–siRNA–treated mice
with GalNAc–MASP-3–siRNA duplex 2. The p values were calculated using ANOVA. *p , 0.05 in comparison with the mice injected with
GalNAc–luciferase–siRNA.
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well as histopathology scores (Figs. 9A, 10A, 15A). To determine
the levels of MASP-1 and MASP-3 proteins in the circulation
time–resolved immunoﬂuorometric assay was used as described
in Materials and Methods (Fig. 15B, C). There was a signiﬁcant
(p = 0.033) decrease of 14.4% in the levels of MASP-3 at day 0 in
mice injected with GalNAc–MASP-3–siRNA duplex 2 compared
with mice injected with GalNAc–luciferase–siRNA (Fig. 15B). At
day 10, there was a signiﬁcant (p = 0.011) decrease of 42% in the
levels of MASP-3 in mice injected with GalNAc–MASP-3–siRNA
duplex 2 compared with mice injected with luciferase siRNAs
(Fig. 15B). No signiﬁcant diﬀerences were seen in the levels of
MASP-1 at any time point before and after injections and also
before and after the induction disease (Fig. 15C). The levels of
MASP-2 andMAp44were not examined because of the limited
amount of serum from each mouse available for these studies.
These data show that therewas an eﬀect on the levels ofMASP-
3 without substantial oﬀ-target eﬀects on MASP-1 in mice
injected with GalNAc–MASP-3–siRNA duplex 2 or GalNAc–
luciferase–siRNA (Fig. 15A–C).
GalNAc–MASP-3–siRNA duplex decreased the expression of
MASP-3 in the liver of mice with CAIA
Upon sacriﬁce, livers from the aboveCAIAmicewere snap frozen.
Total RNA was extracted to examine the expression of MASP-1
and MASP-3 from mice treated with GalNAc–MASP-3–siRNA
duplex 2 or GalNAc–luciferase–siRNA (Fig. 15D, 15E). There was
a signiﬁcant (p = 0.025) decrease in the expression of MASP-3
in the liver of mice with CAIA treated with GalNAc–MASP-3–
siRNA duplex 2 compared with the mice with CAIA treated with
GalNAc–luciferase–siRNA (Fig. 15D). Overall, there was a 31%
decrease in the MASP-3 expression in the liver of CAIA mice
treated with GalNAc–MASP-3–siRNA duplex 2 compared with
the mice with CAIA treated with GalNAc–luciferase–siRNA.
No signiﬁcant change (p = 0.35) was seen for MASP-1 mRNA
abundance in the liver from CAIA mice treated with GalNAc–
MASP-3–siRNA compared with the mice with CAIA treated
with GalNAc–luciferase–siRNA (Fig. 15E). These data show that
GalNAc–MASP-3–siRNA duplex 2 decreased the expression of
MASP-3 and not of MASP-1 in the liver.
FIGURE 11. Representative histopathology images from the knee joints and ankle of CAIA mice injected s.c. with GalNAc–MASP-3–siRNA
duplex 2 or GalNAc–luciferase–siRNA.
The top two panels from left to right (A and B) show staining with T blue (blue color) from the knee joints of CAIA mice treated with GalNAc–
luciferase–siRNA (left panel) or with GalNAc–MASP-3–siRNA duplex 2 (right panel). The second set of two panels from left to right (C and D) show
staining with T blue from the ankle joints of CAIA mice treated with GalNAc–luciferase–siRNA (left panel) or with GalNAc–MASP-3–siRNA duplex 2
(right panel). Areas of synovium (S, arrow), cartilage (C, arrow), bone marrow (BM, arrow), adipose tissue (AD, arrow), synovial cavity (SCAV, arrow),
calcaneus (CA, arrow), talus (T, arrow), and meniscus (M, arrow) are identified. The sections were photographed at original magnification 320. Scale
bars shown in red in the bottom right of each panel for knee joint (A and B), 0.05 mm (50 mm, original magnification 320), and for ankle (C and D),
0.1 mm (100 mm, original magnification 310).
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DISCUSSION
MASP proteins (MASP-1 and MASP-2) were initially identiﬁed
through their interaction with MBL (49–51). MASP-3 was
identiﬁed shortly thereafter, also through interactionswithMBL
(23, 25). MASP-1 and MASP-3 are alternatively splice forms
derived from theMASP1/3 gene along with the additional splice
variant MAp44, whereas MASP-2 is encoded by the separate
MASP2 gene. AlthoughMASP-1 andMASP-3 are derived from the
samegene, their functions are quite diﬀerent.MASP-1 has recently
been shown to activateMASP-2 via a cleavage event, thus enabling
theMASP-2–mediatedcleavageofC2andC4and theconstruction
of the C3 convertase C4b2a for the LP (52, 53). MASP-1 is also
suggested to be responsible for the activation of MASP-3, which,
in contrast to MASP-2, is responsible for the cleavage of proFD to
active FD for the AP (54). ThusMASP-3 is an important regulator
of the AP, whereas MASP-1 is a more general MASP activator.
Gene deletion experiments that generated MASP1/32/2 mice
resulted in both inactivated MASP-1 and MASP-3 functions,
rendering our understanding of the individual roles of these two
enzymes uncertain. Speciﬁc deﬁciency of MASP-3 is rare but has
been observed in humans. Mutations in MASP1 exon 12 render
MASP-3 inactivated and are responsible for the development
of Malpuech–Michels–Mingarelli–Carnevale syndrome (55–57).
This indicates that MASP-3 plays a developmental role as well as
its role in the activation of the AP of complement.
In our studies of the role of MASPs in an experimental
RA, we have previously shown that disruption of the MASP1
gene, resulting in the loss of both MASP-1 and MASP-3,
almost completely blocked disease in the CAIA model (14). Subse-
quently, we found that overexpression of MAp44, a competitive
inhibitor of MASP-1, MASP-2, and MASP-3, nearly completely
blocked the development of disease (5). Dissociation of the eﬀects
of MASP-1 and MASP-3 genetically was technically challeng-
ing, however, requiring the selective disruption of exons unique
to MASP-3.
Progress in thedesignof siRNAs,however, aﬀordedusasecond
option, namely, to design siRNAs that could distinguish between
MASP-1 and MASP-3 mRNAs. We approached this in two ways.
Working with the functional genomics core of the University of
Colorado, we designed shRNA sequences that could be expressed
by lentiviral infection. The lentiviral construct was successful at
targeting human MASP-3 mRNA but not MASP-1 or MASP-2.
HepG2 and T98G cells chosen for both of these are high MASP-
3–expressing cell lines (44). We saw no signiﬁcant change in
MASP-1 transcripts, whereas MASP-3 transcripts were almost
entirely absent after lentiviral infection in T98G cells (Fig. 2C).
Furthermore, the eﬀect was durable and lasting for months in
T98G cells (Supplemental Fig. 2A). In HepG2 cells, no eﬀect was
seen on MASP-1 and MASP-2, whereas there was a signiﬁcant
decrease inMASP-3 (Fig. 2F).High levels ofMASPs inmouse liver
compared with human liver indicate species-speciﬁc diﬀerences.
To evaluate speciﬁc silencing of MASP3 in vivo and mouse
CAIA model, we used Alnylam Pharmaceuticals’ liver-speciﬁc
GalNAc-siRNA delivery technology. The triantennary GalNAc
ligand engages the hepatocyte-speciﬁc ASGPR receptor enabling
siRNA uptake. siRNAs conjugated to a GalNAc have been used
extensively to silence liver-expressed genes in both preclinical
species and in the clinic. This platform has demonstrated robust
clinical translation across multiple liver target genes (42). For
example, Inclisiran (ALN-PCSsc) signiﬁcantly reduced the levels
of PCSK9, a target for low-density lipoprotein (LDL) cholesterol,
FIGURE 12. Representative C3 deposition images from the knee joints of CAIA mice injected s.c. with GalNAc–MASP-3–siRNA duplex 2 or
GalNAc–luciferase–siRNA.
The two panels from left to right (A and B) show IHC C3 staining using anti-C3 Ab (brown color) from the knee joints of CAIA mice treated with
GalNAc–luciferase–siRNA (left panel) or with GalNAc–MASP-3–siRNA duplex 2 (right panel). Areas of synovium (S, arrow), cartilage (C, arrow), bone
marrow (BM, arrow), and meniscus (M, arrow) are identified. The sections were photographed at original magnification 320. Scale bar shown in red
in the bottom right in (A) and (B) for knee joint, 0.1 mm (100 mm).
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for at least 6 mo (43). In contrast, lentiviral constructs are rapidly
cleared when administered systemically (58), making eﬃcient
knockdown of a target by this means diﬃcult. Multiple GalNAc-
siRNA conjugates speciﬁc for mouse MASP3 were designed and
evaluated in in vitro studies and healthymice to select a duplex for
testing in the CAIA model.
The MASP-3 duplex chosen for our in vivo studies decreased
liverMASP-3mRNAby;50% 7 d after a single dose (Fig. 6). In our
ﬁrst CAIA study, however, providing three siRNA doses on days –5,
0, and+3 (relative to inductionofdisease) resulted inanalmost com-
plete elimination of MASP-3 mRNA (Fig. 7D). MASP-3 protein in
the serumhad decreased by 50% (Fig. 6A). Thismay be due, in part,
to other tissue sources for MASP-3 and to the half-life of MASP-3
protein in the serum. CAIA disease progression was attenuated by
the GalNAc–MASP-3–siRNA treatment inmice but not completely
blocked. Histopathology scores for inﬂammation, pannus, cartilage
damage, and bone damage were also consistent with the CDA.
C3 deposition in the knee jointswere also decreased and consistent
with the decrease in MASP-3 deposition in the synovium of knee
joints and forepaws. The attenuation of disease is consistent with
the diminished presence of serumMASP-3 (Fig. 15B).
We have shown that CAIA is dependent on the AP as FD2/2,
MBL A/C/FD2/2, C1q2/2/FD2/2, andMASP-1/32/2mice are re-
sistant to CAIA (14, 59). An essential step in the AP is the cleavage
of proFD to FD. Several groups have shown, using in vitro
methods, that MASP-3 appears to be the essential enzyme that
activates FD. One group has generated inhibitors speciﬁc for
MASP-1, 2, and3, andusing these inhibitorshas shownthatMASP-
3 alone appears to be responsible for proDF cleavage (31). Us-
ing various sera depleted for MASP-3 to varying extents
FIGURE 13. Representative macrophage staining images only from the knee joints of CAIA mice injected s.c. with GalNAc–MASP-3–siRNA
duplex 2 or GalNAc–luciferase–siRNA.
The two panels from left to right (A and B) show IHC macrophage staining using anti-F4/80 Ab (red color) from the knee joints of CAIA mice treated
with GalNAc–luciferase–siRNA (left panel) or with GalNAc–MASP-3–siRNA duplex 2 (right panel). The two panels are showing the enhanced
(original magnification 320) red boxed area of the synovium for clarity. Areas of synovium (S, arrow), cartilage (C, arrow), bone marrow (BM, arrow),
and meniscus (M, arrow) are identified. The sections were photographed at original magnification 310. Scale bars shown in red in the bottom right
of each panel for knee joint, original magnification 320, 0.05 mm (50 mm), and original magnification 310, 0.1 mm (100 mm).
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compromises the conversion of proFD to DF (32). We show, in
vivo, cleavage of proFD to DF and reconstitution of the AP
activation inMASP-1/32/2mice by active rMASP-3 (Fig. 4). This
demonstrates that MASP-3 is suﬃcient to reconstitute the AP in
vivo but does not yet demonstrate that it is necessary. As MASP-1
andMASP-3 are generated by alternative splicing of a single gene,
mice in which one or the other splice forms are genetically
disruptedwill be needed to formally prove this hypothesis in vivo.
Examining the time course of disease development in
GalNAc–MASP-3 siRNA-treated mice, we note that disease
is markedly inhibited through day 6 (69%) (Fig. 9). Then, a rapid
acceleration of disease occurs on day 7 leading to the ﬁnal
inhibition of disease to 50% of control (Fig. 9A). We postulate
that a mini breakthrough of MASP-3 expression may have
occurred at this point. Alternatively, one can speculate that there
is a possibility that an extrahepatic MASP-3 contribution by
brain or inﬂammatory cells could have played a role in the
breakthrough. Although a blood–brain barriermight exist, during
acute inﬂammatory conditions, there could be a mini break-
through in this blood–brain barrier. Although technically
infeasible in this study, a future study will be designed to
examine serum daily for MASP-3 levels to test this hypothesis.
FIGURE 14. IHC localization of MASP-3 protein in joints in mice with arthritis.
Representative images of the joints from WT with CAIA-treated GalNAc–Luc–siRNA and GalNAc–MASP-3 siRNA. The top set of four panels from
left to right (A, C, E, and G) show positive staining with biotinylated anti-mouse MASP-3 (dark brown color) (black arrow) from the liver (first panel),
brain (second panel), knee joints (KJ) (third panel), and forepaws (FP) (last leftmost panel) of WT mice. The hepatocytes (H) (red arrow) present in the
liver were positive for MASP-3, whereas brain (i.e., granular layer cells [GL]) were all strongly positive for MASP-3 (A and C). Many cells were positive
for MASP-3 protein in the synovium (S) from KJ and FP in WT mice with CAIA treated with GalNAc–Luc–siRNA. The middle set of four panels from
left to right (B, D, F, and H) show no staining (no dark brown color) used as negative controls by staining using diluent alone without primary Ab from
the liver (first middle panel) and brain (second middle panel) of WT mice. There were no or few MASP-3–positive cells in the KJ (third middle panel)
and FP (last middle rightmost panel) of WT mice with CAIA treated with GalNAc–MASP-3–siRNA. The single bottom panel shows no MASP-3
staining (no dark brown color) (negative control) from the liver of MASP-1/32/2 mice (I) (bottom panel) as expected. The liver, brain, KJ, and FP
sections stained for MASP-3 deposition were counterstained with H&E and photographed at original magnifications 320 or 340 using Zeiss
Observer. D1 (Axio) microscope. Joint sections were examined in duplicate from WT (n = 7) with CAIA treated with GalNAc–MASP-3–siRNA and
fromWT with CAIA treated with GalNAc–luciferase–siRNA, but representative pictures from each treatment groups have been shown. Red scale bar
shown in (A), (B), (E), and (F), 20 mm. Red scale bar in (C), (D), (G), (H), and (I), 50 mm. CTRL, control. LUC, luciferase.
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Importantly, GalNAc–MASP-1–siRNA had no signiﬁcant ef-
fect on CAIA even after inhibiting more than 95% of MASP-1
expression in the liver aswell asMASP-1 protein in the circulation
(data not shown), suggesting that the contribution of theMASP1/3
gene to CAIA is primarily through MASP-3 but not through
MASP-1, although both are predominately generated by the
liver. Given the suggested role of MASP-1 as an activator of
MASP-3, this result demonstrates the existence of other
activators of MASP-3. We also examined the eﬀect of GalNAc–
MASP-2 siRNA (data not shown) and obtained results similar
to thosewe obtainedwithMASP-22/2mice (34). Given that the
liver is also the major source of MASP-2, this result was
expected. Interestingly, it has been shownusing paired samples
that high levels of MASP-3 versus MASP-2 are present in the
synovial ﬂuid as well as in the plasma of RA patients (17).
Studies combining siRNAs targeting combinations of MASPs
are planned for the future.
A limitation of our study is that liver-targetedMASP-3–siRNA
duplexes did not completely inhibit MASP-3 expression as we
observed MASP-3 protein in the circulation of mice after siRNA
treatment. This may be due to the contribution of other tissues
during acute inﬂammatory conditions or alternatelymay be due to
the inherent stability of MASP-3 protein. Indeed, although we
know that transcripts from the MASP1 gene derive from other
tissues besides liver (44), we do not yet know the tissue speciﬁc-
ity of the splicing event. Furthermore, we have no information
on the rate of turnover of MASP-3 during steady state or during
inﬂammation.All of theseparameterswill aﬀect our interpretation
of the data presented in this study. Thus, the partial inhibition of
diseasemay simplybedue to thepartial removal of serumMASP-3.
FIGURE 15. A Long-term effect of GalNAc–MASP-3–siRNA duplex 2 on MASP-1 and on MASP-3 protein in the circulation and expression in the
liver before and after the development of CAIA in mice.
(A) Western blot showing a long-term effect on the levels of MASP-3 protein at day 10 in the sera from mice with CAIA treated with GalNAc–MASP-
3–siRNA duplex 2 only (lanes 3 and 4). (B) ELISA showing the levels of MASP-3 protein at day 0 and at day 10 in mice with CAIA injected with
GalNAc–MASP-3–siRNA duplex 2 compared with the mice with CAIA injected with GalNAc–luciferase–siRNA. (C) ELISA showing no differences in
the levels of MASP-1 protein at day 0 and at day 10 in mice with CAIA injected with GalNAc–MASP-3–siRNA duplex 2 compared with the mice with
CAIA injected with luciferase siRNAs. (D) MASP-3 expression in the liver from mice injected with GalNAc–MASP-3–siRNA duplex 2 (E). No off-target
effect in the expression of MASP-1 in the liver from CAIA mice injected with GalNAc–MASP-3–siRNA duplex 2 compared with liver from CAIA mice
injected with GalNAc–luciferase–siRNA. 18s RNA was used as an internal control and to calculate the expression of MASP-1 and MASP-3 in the liver
for qRT-PCR. Western blot bands have been cut from the original blot to show the specific days of MASP-3 inhibition along at day 10 consistent with
the liver MASP-3 expression data at day 10. Data from all mice have been included. The p values were calculated using t test. *p , 0.05 versus mice
injected with GalNAc–luciferase–siRNAs were compared.
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This question can only be answered by the construction of a
MASP-3 exon tissue-speciﬁc knockout mouse strategy, allowing
removal of all MASP-3 or tissue-speciﬁc expression while leaving
MASP-1 and MAp44 intact.
The liver is seldom thought of as an organ associated with
joint disease in RA. Given its role as a major source of soluble
complement components (10, 11, 34), we suggest that this role
should be reconsidered. Recently, it has been proposed that the
etiology of RA involves a combination of genetics and epigenetics
leading to an increased likelihood of developing an immune
response to posttranslationally altered self (8). Deposition of Ab
within the synovial space leads to the initiation of a joint speciﬁc
immune response. This, however, is not suﬃcient. For the re-
sponse to become self-sustaining, we propose that a second hit of
liver-speciﬁc secretion of complement components necessary for
theAP is necessary. Our treatment schedule (injections on days–5,
0, and +3 or on day –10, day –5, or day 0) has focused on the role
of complement in the early phase of RA disease development.
It will be important to employ our GalNAc–MASP-3–siRNA
therapeutics in established disease to test whether complement
remains a driver at all times or just at early times.
Given the importance of complement for innate immunity,
it is likely that a therapeutic that strongly inhibits this systemmay
increase susceptibility for infections. In this regard, it is, perhaps,
beneﬁcial that the GalNAc–MASP-3–siRNA only partially blocks
MASP-3 protein levels. Interestingly, a recent study found that
relatively small amounts of FD are suﬃcient to activate the AP
in mice (60). Because MASP-3 deposition was low in the joints,
we speculate that a small amount of MASP-3 can activate the
AP locally or systemically. This idea is supported by the fact that
MASP-1/3+/2mice,whichhave suboptimal levels ofMASP-3,were
equally susceptible to CAIA when comparing with the WT mice
(data not shown).
In conclusion, this represents theﬁrst study, to our knowledge,
invivodemonstrating an important roleofMASP-3 (separate from
MASP-1) in thedevelopmentofRA. It supports the contention that
the liver plays an important role in RA and supplies a candidate
enabling the second hit to drive disease. Finally, it provides
a further demonstration of the therapeutic potential for novel
GalNAc–MASP-3–siRNA duplexes.
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